Clik here to view.
Tekmira’s leading RNAi platform ready for prime time
As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the...
View ArticleClik here to view.
Tekmira partner starts human trials of ALN-TTR01
Alnylam Pharmaceuticals (NASDAQ:ALNY), one of Tekmira Pharmaceuticals‘ (TSX:TKM) partners, has initiated dosing in a Phase 1 clinical trial of its ALN-TTR01 product candidate in patients with...
View ArticleClik here to view.
Alnylam presents positive preliminary data for ALN-TTR01
Alnylam Pharmaceuticals (NASDAQ: ALNY) has presented positive preliminary results at a medical conference in Japan from its Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting...
View ArticleClik here to view.
Rodman ups Alnylam price target to $19
Rodman & Renshaw has raised its year-end price target for “market outperform-rated” Alnylam Pharmaceuticals (NASDAQ:ALNY) to $19 from $12, based on changes to the company’s business model and a...
View Article
